Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 4/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345594 | 0.84 | CCR5 (0.41) | CCR5GPR119TLR8DRD2DRD3 | |
| SCHEMBL346049 | 0.82 | GPR119 (0.36) | GPR119CYP1A2 | |
| SCHEMBL347439 | 0.81 | TLR8 (0.45) | CCR5GPR119TLR8DRD2DRD3 | |
| SCHEMBL118654 | 0.75 | CYP1A2 (0.50) | GPR119CYP1A2 | |
| SCHEMBL10263386 | 0.74 | CYP2D6 (0.46) | CCR5GPR119TLR8 | |
| Hydrochloric Acid SCHEMBL2075849 | 0.74 | CYP1A2 (0.49) | GPR119CYP1A2 | |
| SCHEMBL4067693 | 0.73 | DRD2 (0.37) | DRD2DRD3CYP1A2 | |
| SCHEMBL30049604 | 0.73 | CYP2D6 (0.44) | CCR5GPR119NAMPT | |
| SCHEMBL30234012 | 0.71 | GPR119 (0.43) | CCR5GPR119TLR8 | |
| SCHEMBL485158 | 0.71 | CYP1A2 (0.49) | GPR119CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073662-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI (FR) | 2014-03-13 | — | — | US | disclosed |
| US-8609681-B2 | Spirocyclic nitriles as protease inhibitors | SANOFI (FR) | 2013-12-17 | — | — | US | disclosed |
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | CCR5 2227/4885GPR119 4318/4885TLR8 3990/4885 |
| US-20140073662-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | CCR5 2227/4885GPR119 4318/4885TLR8 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.